

Risk Factors of Restenosis on the Antiplatelet Therapy

Taizhanova Dana^{1*}, Toleuova Aliya², Bodaubay R.³ and Kalimbetova A.⁴

^{1,2,3,4}Karaganda Medical University, Kazakhstan

Abstract

Introduction: The aim of this work is to assess the risk factors for restenosis on the antiplatelet therapy background after PCI.

Materials: A questionnaire was tested on patients after PCI who received double and triple antiplatelet therapy. A survey was conducted in 60 patients who were divided into 2 groups. First group was basic. It included 30 patients with coronary artery restenosis after PCI. Second group was control. It included 30 patients with coronary artery disease without restenosis. Study design was case control.

Results: An analysis was made of the patients' case histories with a restenosis while taking dual antiplatelet therapy. The subjects were 55 ± 10 years old. In the studied groups, the proportion of women was 44%, men 56%. According to questionnaire, the smoker's index exceeded 20 points OR = 1.8-95% CI [0.68-1.14]. When analyzing the heredity among patients of both of groups revealed OR = 1.14, (95% CI [0.45-0.55]). In the main group determined (coronary heart disease, hypertension, fatal cardiovascular events) (OR = 2.7 95% CI [3.65-2.49]) and less in the control group (without restenosis) - OR = 1.2 (95% CI [-1.05 - (- 0.85)]). According to anthropometry, overweight was detected in 42% of the subjects, obesity - in 31%, which is an OR of 1.36 and 1.5 respectively. Among concomitant diseases, type 2 diabetes mellitus was often found, but the risk of restenosis in such patients was 1 (95% CI [0.76 - (- 1.8)]). The coagulation test showed the APTT shortening and hyperfibrinogenemia, which amounted to OR = 4.6 and 1.6, respectively. The lipid profile in 70% corresponded to reference values.

Conclusions: The combination of risk factors in patients with restenosis was higher than in patients without restenosis.



Biography:

Taizhanova Dana. Head of Internal medicine department, head of educational program on Cardiology. Teacher of residents and physicians on Internal diseases and Cardiology. Head of scientific project on the problem of thrombosis and restenosis of coronary artery. Member of Russian and Europe Cardiologists Association.

Speaker Publications:

1. O.Visternichan, S.Farhad Jalali, D.Taizhanova, L.Muravlyova,G.Igimbaeva. Dynamic changes in purin catabolism in patients with acute coronary syndrome that underwent percutaneous coronary intervention. Caspian J.Intern Med ,2019;10/1:86-91.
2. Taizhanova D.Zh., Visternichan O.A.Risk of restenosis after coronary stentinc. //HIGHLIGHTS OF THE. - 23 rd International congress on thrombosis 2014.- Sarm el-sneikn – Egypt hyatt.- 29-31 january 2015.
3. Zhunussov Y1, Taizhanova D1, Abdullabekova R1, Bitz U1, Visternichan O
Optimum application of modern antithrombotic drugs among patients with the acute coronary syndrome with the risk of stricture formation of coronary arteries. Georgian Medical News. -2016 Feb;(251):40-5.
4. Taizhanova D., Zoldybayeva E., Tarlykov P. Clinico – laboratory predictors of coronary restenosis in man of Kazakh nationality. - //Thrombosis research. Abstracts of the 24th Biennial International Congress on Thrombosis – EMLTD Congress 2016 4-7 May 2016, Istanbul, Turkey. ISSN 0049-3848-. P. 39.
5. Toleuova A., Taizhanova D., Beysenbekova Z., Tauesheva Z., Guseinova Z., Toyynbekova R., Visternichan O., Zhusupova A., Mandybayeva M., Kenzhetaeva Z. The treatment of venous thromboembolism //Thrombosis research. Abstracts of the 24th Biennial International Congress on Thrombosis, 4-7 May 2016, Istanbul, Turkey. ISSN 0049-3848.- P. 23-24

[23rd Edition of International Conference on Insights by Cardiologists](#) London, UK- March 23-24, 2020

Abstract Citation:

Taizhanova Dana, Head of Internal medicine department, Karaganda Medical University, Karaganda, Kazakhstan – A General Study, Cardiologists 2020, 23rd Edition of International Conference on Insights by Cardiologists: London, UK March 23-24, 2020